<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131910</url>
  </required_header>
  <id_info>
    <org_study_id>2010-019438-28</org_study_id>
    <nct_id>NCT01131910</nct_id>
  </id_info>
  <brief_title>TBE-vaccine to Patients With Rheumatoid Arthritis Who Are Using Immunosuppressive Drugs</brief_title>
  <official_title>Efficacy of TBE-vaccine to Patients With Rheumatic Disease Who Are Treated With Methotrexate and/or TNF-alfa Blocking Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sormland County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sormland County Council, Sweden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intend to check whether the efficacy of a TBE-vaccine is substantially
      deteriorated in patients with rheumatoid arthritis who are treated with drugs which suppress
      the immune system. The investigators aim to detect a difference of at least 10 % compared to
      healthy individuals (historical controls) in protection when analysed with serology. If the
      investigators detect a difference, the investigators will continue to explore whether
      protection can be achieved by additional doses
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>1 year</time_frame>
    <description>The humoral response to TBE-vaccine</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Exposed to TBE-virus</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Vaccination against TBE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Less than 60 years old: Two doses of TBE- vaccine separated by a month and a third dose 12 months after the first dose
60 years and above: Three doses, given at 0+1+3 months and a 4 th dose 12 months after the first dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TBE-vaccine</intervention_name>
    <description>Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)</description>
    <arm_group_label>Vaccination against TBE</arm_group_label>
    <other_name>ATC-code J07B A01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TBE-vaccine</intervention_name>
    <description>Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year</description>
    <arm_group_label>Vaccination against TBE</arm_group_label>
    <other_name>J07B A01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination against TBE</intervention_name>
    <description>0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)</description>
    <arm_group_label>Vaccination against TBE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatoid arthritis treated with methotrexate and/or TNF-alfa blocking drugs

          -  Interest to be vaccinated

          -  Written consent

          -  Age 18 years or more

        Exclusion Criteria:

          -  Previous TBE-infection

          -  Previous Vaccination with TBE

          -  Pregnancy

          -  Breast feeding

          -  Treatment with rituximab the last 9 months

          -  Inability to follow study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Rombo, MD Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Somland county council</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Helsingfors</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Eskilstuna</city>
        <zip>631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. infectious diseases</name>
      <address>
        <city>Eskilstuna</city>
        <zip>631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of infectious diseases</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of infectious diseases</name>
      <address>
        <city>Ã–rebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>May 24, 2011</last_update_submitted>
  <last_update_submitted_qc>May 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Professor Lars Rombo</name_title>
    <organization>Sormland County Council</organization>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>TBE-vaccine</keyword>
  <keyword>Immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

